Nektar Therapeutics reports results for the quarter ended December 31 - Earnings Summary

Nektar Therapeutics

12/03/2025 21:38

Nektar Therapeutics NKTR.OQ reported quarterly adjusted earnings of 3 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -22 cents.  The mean expectation of nine analysts for the quarter was for a loss of 17 cents per share. Wall Street expected results to range from -21 cents to -10 cents per share.

Revenue rose 22.1% to $29.18 million from a year ago; analysts expected $29.86 million.

Nektar Therapeutics's reported EPS for the quarter was 3 cents​.

The company reported quarterly net income of $7.26 million.

Nektar Therapeutics shares had fallen by 11.9% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 3.7% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 3 "hold" and 1 "sell" or "strong sell."

The average consensus recommendation for the biotechnology & medical research peer group is  "hold."

Wall Street's median 12-month price target for Nektar Therapeutics is $4.00

This summary was machine generated from LSEG data March 12 at 09:37 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
-0.17
0.03
Beat
Sep. 30 2024
-0.21
-0.18
Beat
Jun. 30 2024
-0.20
-0.25
Missed
Mar. 31 2024
-0.19
-0.19
Met